FDAnews
www.fdanews.com/articles/96544-lev-pharmaceuticals-submits-biologics-license-application-for-cinryze

Lev Pharmaceuticals Submits Biologics License Application for Cinryze

July 31, 2007

Lev Pharmaceuticals, Inc. announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of its C1 inhibitor, proposed to be marketed as Cinryze, for the acute treatment of hereditary angioedema (HAE).
CNN Money